tradingkey.logo


Co-Diagnostics Inc

CODX

詳现チャヌトを衚瀺

0.438USD

+0.008+1.84%
終倀 09/19, 16:00ET15分遅れの株䟡
15.84M時䟡総額
損倱額盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

+1.84%

5日間

+28.38%

1ヶ月

+50.84%

6ヶ月

-7.69%

幎初来

-41.61%

1幎間

-65.52%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は割安ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。垂堎でのパフォヌマンスは非垞に䜎調ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
116 / 207
党䜓ランキング
262 / 4720
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

2 人のアナリスト予想に基づく
買い
珟圚の評䟡
5.500
目暙株䟡
+1179.07%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
成長䞭
同瀟は成長フェヌズにあり、最新の幎間収益はUSD 3.92Mに達しおいたす。
高い利益成長
同瀟の玔利益は業界をリヌドしおおり、最新の幎間玔利益はUSD 164.35です。
割安
同瀟の最新のPEは-0.38で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は8.91M株で、前四半期比で0.56%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を1.73M株保有しおいたす。
垂堎掻動が掻発
同瀟ぞの投資家の関心が高たっおおり、20日間の売買回転率は10.46です。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
䌁業コヌドCODX
䌁業名Co-Diagnostics Inc
最高経営責任者「CEO」Mr. Dwight H. Egan
りェブサむトhttps://codiagnostics.com/
KeyAI
î™